{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:48:35Z","timestamp":1758808115822,"version":"3.44.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.ucl.2006.06.003","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T09:28:46Z","timestamp":1168421326000},"page":"439-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Oxybutynin in Detrusor Overactivity"],"prefix":"10.1016","volume":"33","author":[{"given":"Ananias","family":"Diokno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ingber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ucl.2006.06.003_bib1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1021\/jm00329a044","article-title":"Anticholinergic agents. Esters of 4-Dialkyl- (or 4-Polymethylene-) amino-2-butynols","volume":"8","author":"Majewski","year":"1965","journal-title":"J Med Chem"},{"issue":"2A","key":"10.1016\/j.ucl.2006.06.003_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0090-4295(98)90009-7","article-title":"Pharmacologic options for the overactive bladder","volume":"51","author":"Wein","year":"1998","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.ucl.2006.06.003_bib3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0022-5347(17)60721-3","article-title":"Oxybutynin: a new drug with analgesic and anticholinergic properties","volume":"108","author":"Diokno","year":"1972","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2006.06.003_bib4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1464-410X.1980.tb03093.x","article-title":"The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride","volume":"52","author":"Moisey","year":"1980","journal-title":"Br J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2006.06.003_bib5","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0022-5347(17)45940-4","article-title":"Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia","volume":"135","author":"Gajewski","year":"1986","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2006.06.003_bib6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000472508","article-title":"Oxybutynin and the prevention of urinary incontinence in spina bifida","volume":"11","author":"Hehir","year":"1985","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2006.06.003_bib7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0022-5347(17)38459-8","article-title":"Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo","volume":"145","author":"Thuroff","year":"1991","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2006.06.003_bib8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/00002512-199506030-00007","article-title":"Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability","volume":"6","author":"Yarker","year":"1995","journal-title":"Drugs Aging"},{"issue":"Suppl 5A","key":"10.1016\/j.ucl.2006.06.003_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0090-4295(99)00492-6","article-title":"Muscarinic receptor antagonists in the treatment of overactive bladder","volume":"55","author":"Chapple","year":"2000","journal-title":"Urology"},{"issue":"12","key":"10.1016\/j.ucl.2006.06.003_bib10","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2165\/00002018-200225120-00004","article-title":"Benefit-risk assessment of extended-release oxybutynin","volume":"25","author":"Michel","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.ucl.2006.06.003_bib11","unstructured":"Oxybutynin chloride, package insert. Alza Corporation, Mountain View, California. June 2004."},{"issue":"6","key":"10.1016\/j.ucl.2006.06.003_bib12","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1464-410X.2004.05040.x","article-title":"Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder","volume":"94","author":"Preik","year":"2004","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.ucl.2006.06.003_bib13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3109\/00498259209053145","article-title":"Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application in pharmacokinetic studies in young, elderly and frail elderly volunteers","volume":"22","author":"Hughes","year":"1992","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ucl.2006.06.003_bib14","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0022-5347(01)62828-3","article-title":"Intravesical oxybutynin for neurogenic bladder dysfunction: less systematic side effects due to reduced first pass metabolism","volume":"160","author":"Buyse","year":"1998","journal-title":"J Urol"},{"issue":"21","key":"10.1016\/j.ucl.2006.06.003_bib15","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.lfs.2004.11.013","article-title":"In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin","volume":"76","author":"Oki","year":"2005","journal-title":"Life Sci"},{"key":"10.1016\/j.ucl.2006.06.003_bib16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.0306-5251.2001.01463.x","article-title":"Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride","volume":"52","author":"Sathyan","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ucl.2006.06.003_bib17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/(SICI)1520-6777(1997)16:6<533::AID-NAU3>3.0.CO;2-F","article-title":"Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients","volume":"16","author":"Nilsson","year":"1997","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"10.1016\/j.ucl.2006.06.003_bib18","article-title":"The evolution of oxybutynin chloride","volume":"167","author":"Diokno","year":"2002","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2006.06.003_bib19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0025-6196(11)62382-3","article-title":"Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study","volume":"76","author":"Appell","year":"2001","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.ucl.2006.06.003_bib20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","article-title":"OPERA Study Group. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial","volume":"78","author":"Diokno","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ucl.2006.06.003_bib21","unstructured":"Appell R, Boone T. Effects of extended-release formulations of oxybutynin and tolterodine on nocturnal voiding frequency on women with overactive bladder. Presented at the 35th Annual Meeting of the International Continence Society. Montreal, Canada, August 2005."},{"issue":"4","key":"10.1016\/j.ucl.2006.06.003_bib22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1464-410X.2003.04351.x","article-title":"Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response","volume":"92","author":"Malone-Lee","year":"2003","journal-title":"Br J Urol Int"},{"issue":"1","key":"10.1016\/j.ucl.2006.06.003_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/A:1021372426421","article-title":"Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study","volume":"34","author":"Diokno","year":"2002","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"10.1016\/j.ucl.2006.06.003_bib24","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.ajog.2005.03.036","article-title":"Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial","volume":"192","author":"Chu","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"2 Pt 1","key":"10.1016\/j.ucl.2006.06.003_bib25","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/01.ju.0000103274.38694.b1","article-title":"Can higher doses of oxybutynin improve efficacy in neurogenic bladder?","volume":"171","author":"Bennett","year":"2004","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2006.06.003_bib26","first-page":"1168","article-title":"Effects of oxybutynin on vesicoureteral reflux in children","volume":"134","author":"Homsy","year":"1985","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2006.06.003_bib27","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0022-5347(17)56996-7","article-title":"Enuresis\u2014principles of management and result of treatment","volume":"121","author":"Kass","year":"1979","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2006.06.003_bib28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF00195921","article-title":"Plasma levels of oxybutynin chloride in children","volume":"46","author":"Autret","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ucl.2006.06.003_bib29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0090-4295(01)01569-2","article-title":"Preliminary study of the safety and efficacy of extended-release oxybutynin in children","volume":"59","author":"Kogan","year":"2002","journal-title":"Urology"},{"issue":"8","key":"10.1016\/j.ucl.2006.06.003_bib30","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1442-2042.2004.00871.x","article-title":"Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience","volume":"11","author":"Saito","year":"2004","journal-title":"Int J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2006.06.003_bib31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0090-4295(03)00356-X","article-title":"Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence","volume":"62","author":"Dmochowski","year":"2003","journal-title":"Urology"},{"issue":"11","key":"10.1016\/j.ucl.2006.06.003_bib32","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2165\/00002512-200320110-00007","article-title":"Transdermal oxybutynin: for overactive bladder","volume":"20","author":"Bang","year":"2003","journal-title":"Drugs Aging"},{"issue":"11\u201312","key":"10.1016\/j.ucl.2006.06.003_bib33","first-page":"691","article-title":"[Therapeutic effects of intrarectal administration of oxybutynin]","volume":"55","author":"Radziszewski","year":"2002","journal-title":"Wiadomosci Lekarskie"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014306000620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014306000620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:18:54Z","timestamp":1758806334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014306000620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0094014306000620"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2006.06.003","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxybutynin in Detrusor Overactivity","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2006.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}